| scholarly article | Q13442814 |
| P50 | author | Floor Backes | Q38643301 |
| David E. Cohn | Q39381089 | ||
| Feng Gao | Q43276868 | ||
| Louise A. Brinton | Q58623846 | ||
| P2093 | author name string | Richard J Zaino | |
| Colin C Pritchard | |||
| Heather A Lankes | |||
| Paul A DiSilvestro | |||
| Heather Hampel | |||
| Matthew A Powell | |||
| Lisa M Landrum | |||
| Shamshad Ali | |||
| Paul J Goodfellow | |||
| Amy P Schmidt | |||
| Melissa A Geller | |||
| Shashikant B Lele | |||
| Michael L Pearl | |||
| Caroline C Billingsley | |||
| David Mutch | |||
| Nilsa Ramirez | |||
| Russell J Broaddus | |||
| Alexis S Chassen | |||
| Luke V Simmons | |||
| P2860 | cites work | ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes | Q27851472 |
| Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions | Q28248318 | ||
| Molecular Analysis of Familial Endometrial Carcinoma: A Manifestation of Hereditary Nonpolyposis Colorectal Cancer or a Separate Syndrome? | Q59244843 | ||
| Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients | Q80050907 | ||
| Are prediction models for Lynch syndrome valid for probands with endometrial cancer? | Q84316559 | ||
| Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer | Q28249924 | ||
| A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer | Q28289377 | ||
| Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. | Q30413346 | ||
| Risks of Lynch syndrome cancers for MSH6 mutation carriers | Q30492977 | ||
| The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history | Q30501708 | ||
| Improving identification of lynch syndrome patients: a comparison of research data with clinical records | Q30580847 | ||
| Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? | Q33593851 | ||
| Endometrial cancer and a family history of cancer. | Q33737568 | ||
| Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer | Q33874719 | ||
| Cost-effectiveness and diagnostic effectiveness analyses of multiple algorithms for the diagnosis of Lynch syndrome | Q34543387 | ||
| Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers | Q35022384 | ||
| Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. | Q35063442 | ||
| A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome | Q35119757 | ||
| Comparative effectiveness of screening strategies for Lynch syndrome. | Q35474031 | ||
| Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers | Q35623021 | ||
| ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing | Q36081155 | ||
| Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases | Q36094483 | ||
| MLH1 methylation screening is effective in identifying epimutation carriers | Q36403949 | ||
| Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas | Q37038863 | ||
| Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention | Q37288004 | ||
| Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers | Q37288374 | ||
| Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the Colon Cancer Family Registry | Q37537200 | ||
| Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines | Q37659105 | ||
| Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma | Q40641250 | ||
| Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk | Q41685035 | ||
| Milestones of Lynch syndrome: 1895-2015. | Q43864989 | ||
| One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome | Q46565810 | ||
| One size may not fit all: the debate of universal tumor testing for Lynch syndrome | Q47397560 | ||
| Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome | Q50776571 | ||
| Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. | Q51065192 | ||
| Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. | Q54532022 | ||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microsatellite | Q265193 |
| Lynch syndrome | Q783644 | ||
| immunohistochemistry | Q899285 | ||
| gynecologic oncology | Q5625186 | ||
| P304 | page(s) | 4301-4308 | |
| P577 | publication date | 2015-11-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study | |
| P478 | volume | 33 |
| Q64100755 | A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips? |
| Q38798530 | Advances in Hereditary Colorectal and Pancreatic Cancers |
| Q47140946 | An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. |
| Q30275239 | Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer |
| Q39668107 | Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study |
| Q100524954 | Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening |
| Q53251839 | Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. |
| Q89723158 | Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma |
| Q91895870 | Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China |
| Q94587266 | Comparison of two Lynch screening strategies in endometrial cancer in a California health system |
| Q48952576 | Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age. |
| Q58726243 | DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer |
| Q57163933 | Endometrial cancer: Molecular markers and management of advanced stage disease |
| Q38852405 | Endometrial cancer: Not your grandmother's cancer |
| Q41726020 | Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival |
| Q104802091 | Evaluation of a nationwide Dutch guideline to detect Lynch syndrome in patients with endometrial cancer |
| Q38737111 | Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation |
| Q37597192 | Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? |
| Q88716106 | Hereditary Colorectal Polyposis and Cancer Syndromes: A Primer on Diagnosis and Management |
| Q36302529 | Identification of endometrial cancer methylation features using combined methylation analysis methods |
| Q47935364 | Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer |
| Q57820122 | Injection-Induced Moment Release Can Also Be Aseismic |
| Q92303085 | Is immunohistochemistry-based screening for Lynch syndrome in endometrial cancer effective? The consent's the thing |
| Q55303640 | Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review. |
| Q89068586 | MSI detection and its pitfalls in CMMRD syndrome in a family with a bi-allelic MLH1 mutation |
| Q28077183 | Major clinical research advances in gynecologic cancer in 2015 |
| Q92628365 | Microsatellite instability in endometrial cancer: New purpose for an old test |
| Q55264193 | Microsatellite instability in prostate cancer by PCR or next-generation sequencing. |
| Q49787899 | Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer |
| Q90611136 | Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker |
| Q90611293 | Mismatch repair in endometrioid endometrial cancer: Increasing our therapeutic proficiency by capitalizing on molecular deficiency |
| Q28078792 | New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care |
| Q97546037 | Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens |
| Q91941146 | Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis |
| Q48478518 | Practical guidance for mismatch repair-deficiency testing in endometrial cancer. |
| Q38857539 | Precancer Atlas to Drive Precision Prevention Trials. |
| Q47745633 | Prevalence and prognostic role of mismatch repair gene defect in endometrial cancer patients |
| Q47660108 | Prevalence of Lynch syndrome in unselected patients with endometrial or ovarian cancer. |
| Q93385190 | Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma |
| Q53081522 | Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. |
| Q50720259 | Targeted Screening With Combined Age- and Morphology-Based Criteria Enriches Detection of Lynch Syndrome in Endometrial Cancer |
| Q91394232 | Targeted next-generation sequencing in the detection of mismatch repair deficiency in endometrial cancers |
| Q102062996 | Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy |
| Q63966105 | The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome |
| Q90953408 | The practice of universal screening for Lynch syndrome in newly diagnosed endometrial carcinoma |
| Q57688893 | The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol |
| Q92000687 | The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis |
| Q88801413 | Towards value-based universal Lynch syndrome identification in endometrial cancer patients |
| Q39026764 | Traditional Approaches to Molecular Genetic Analysis |
| Q92438494 | Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? |
| Q104739131 | Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative |
| Q54056109 | Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. |
| Q51421660 | Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. |
| Q47908752 | Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial |
Search more.